M
Matthew Rausch
Researcher at University of Arizona
Publications - 31
Citations - 1757
Matthew Rausch is an academic researcher from University of Arizona. The author has contributed to research in topics: Immune system & Tumor microenvironment. The author has an hindex of 10, co-authored 27 publications receiving 1276 citations. Previous affiliations of Matthew Rausch include Lafayette College.
Papers
More filters
Journal ArticleDOI
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda,Karen Messer,Natacha Ralainirina,Hongying Li,Christopher J. Leem,Sara Gorjestani,Gyunghwi Woo,Abraham V. Nguyen,Camila C. Figueiredo,Camila C. Figueiredo,Philippe Foubert,Michael C. Schmid,Melissa Pink,David G. Winkler,Matthew Rausch,Vito J. Palombella,Jeffery L. Kutok,Karen McGovern,Kelly A. Frazer,Xuefeng Wu,Michael Karin,Roman Sasik,Ezra E.W. Cohen,Judith A. Varner +23 more
TL;DR: This work demonstrates that therapeutic targeting of intracellular signalling pathways that regulate the switch between macrophage polarization states can control immune suppression in cancer and other disorders.
Journal ArticleDOI
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
Olivier De Henau,Matthew Rausch,David W. Winkler,Luis Felipe Campesato,Cailian Liu,Daniel Hirschhorn Cymerman,Sadna Budhu,Arnab Ghosh,Melissa Pink,Jeremy Tchaicha,Mark Douglas,Thomas T. Tibbitts,Sujata Sharma,Jennifer Proctor,Nicole Kosmider,Kerry White,Howard M. Stern,John Soglia,Julian Adams,Vito J. Palombella,Karen McGovern,Jeffery L. Kutok,Jedd D. Wolchok,Jedd D. Wolchok,Taha Merghoub +24 more
TL;DR: It is demonstrated that targeting PI3Kγ with a selective inhibitor can reshape the tumour immune microenvironment and promote cytotoxic-T-cell-mediated tumour regression without targeting cancer cells directly.
Journal ArticleDOI
IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors.
Jonathan H. DeLong,Aisling O’Hara Hall,Aisling O’Hara Hall,Matthew Rausch,Devapregasan Moodley,Joseph A Perry,Jeongho Park,Anthony T. Phan,Daniel P. Beiting,Ross M. Kedl,Jonathan A. Hill,Christopher A. Hunter +11 more
TL;DR: In vivo overexpression of IL-27 in mice led to increased T cell expression of PD-L1, LAG-3, TIGIT, and TIM-3 and affirm the critical role of TCR signals in the induction of IR expression but find that during infection, IL- 27 promotes T cellexpression of IR.
Journal ArticleDOI
GILT Accelerates Autoimmunity to the Melanoma Antigen Tyrosinase-Related Protein 1
Matthew Rausch,Kari R. Irvine,Paul A. Antony,Nicholas P. Restifo,Peter Cresswell,Peter Cresswell,K. Taraszka Hastings +6 more
TL;DR: It is shown that γ-IFN–inducible lysosomal thiol reductase (GILT) is required for efficient MHC class II-restricted processing of a TRP1 epitope in vitro and accelerates the onset of vitiligo inTRP1-specific TCR transgenic mice.
Journal Article
An Orally Active Small Molecule TGF-β Receptor I Antagonist Inhibits the Growth of Metastatic Murine Breast Cancer
Matthew Rausch,Tobias Hahn,Lalitha V. Ramanathapuram,Deborah Bradley-Dunlop,Daruka Mahadevan,Melania E. Mercado-Pimentel,Raymond B. Runyan,David G. Besselsen,Xiamei Zhang,H.-Kam Cheung,Wen Cherng Lee,Leona E. Ling,Emmanuel T. Akporiaye +12 more
TL;DR: The data indicate that the antitumor efficacy of SM16 is dependent on an immune-mediated mechanism and that SM16 may represent a safe and effective treatment for metastatic breast cancer.